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ABSTRACT
The most important reason for therapy failure in pediatric acute myeloid 
leukemia (AML) is relapse. In order to identify miRNAs that contribute to the clonal 
evolution towards relapse in pediatric AML, miRNA expression profiling of 127 de novo 
pediatric AML cases were used. In the diagnostic phase, no miRNA signatures could 
be identified that were predictive for relapse occurrence, in a large pediatric cohort, 
nor in a nested mixed lineage leukemia (MLL)-rearranged pediatric cohort. AML with 
MLL- rearrangements are found in 15-20% of all pediatric AML samples, and reveal 
a relapse rate up to 50% for certain translocation partner subgroups. Therefore, 
microRNA expression profiling of six paired initial diagnosis-relapse MLL-rearranged 
pediatric AML samples (test cohort) and additional eight paired initial diagnosis-
relapse samples with MLL-rearrangements (validation cohort) was performed. A list of 
53 differentially expressed miRNAs was identified of which the miR-106b~25 cluster, 
located in intron 13 of MCM7, was the most prominent. These differentially expressed 
miRNAs however could not predict a relapse in de novo AML samples with MLL-
rearrangements at diagnosis. Furthermore, higher mRNA expression of both MCM7 and 
its upstream regulator E2F1 was found in relapse samples with MLL-rearrangements. 
In conclusion, we identified the miR-106b~25 cluster to be upregulated in relapse 
pediatric AML with MLL-rearrangements.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous 
disease characterized by various molecular and 
cytogenetic abnormalities, like chromosome 
rearrangements and mutations in different genes [1]. 
Although survival rates have improved over the last 
decade, still overall survival does not exceed 70% in most 
biological groups [2]. Pediatric AMLs with mixed lineage 
leukemia (MLL) rearrangements (or KMT2A, lysine (K)-
specific methyltransferase 2A) represent about 20% of all 
pediatric AML patients [3]. The clinical outcome of this 
group, in general, is intermediate, however substantial 
differences in overall survival related to certain MLL 
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translocation partners have been reported. In particular 
cases with t(10;11)(p12;q23), t(10;11)(p11.2,q23), or 
t(6;11)(q27;q23) represent a very poor-risk group, mainly 
due to early relapses. Approximately 50% of AML patients 
with t(10;11) and t(6;11) MLL-rearrangements will relapse 
during or after therapy [4]. The biological processes that 
determine relapse and subsequent therapy failure in MLL-
rearranged AML are largely unknown.
Gene expression is regulated via transcription, RNA 
processing, and mRNA translation. Recently microRNAs 
(miRNAs) have been identified to control expression of 
relevant leukemogenic drivers. MiRNAs are the epigenetic 
fine-tuners of gene expression, and deregulation has been 
described in a variety of human cancer types, including 
adult AML [5]. MicroRNA genes are often found in 
chromosomal regions that are deleted, amplified or 
involved in translocations in cancer [6, 7]. MiRNAs can 
act as tumor suppressors as well as oncogenes [8]. This 
is determined by cell type and physiological context [9]. 
For instance, the oncogenic miR-17~92 cluster has been 
shown to be overexpressed in MLL-rearranged acute 
leukemias probably due to amplification of the genomic 
locus 13q31.3 and by direct upregulation caused by 
MLL fusion genes [10, 11]. Due to epigenetic modifying 
properties, miRNAs play an important role in the 
translation of mRNA into protein [12].
However, to date, the role of miRNAs in 
leukemogenesis in pediatric AML, especially in the 
process of clonal expansion towards relapse is limited. 
The aim of this study was to determine whether 
specific miRNAs are involved in, or can predict relapse 
development in general and, in particular, in MLL-
rearranged pediatric AML.
RESULTS
MicroRNA profiling in a cohort of 127 de novo 
AML cases was performed recently by Emmrich et al [13]. 
To explore whether relapse can be predicted in de novo 
setting of pediatric AML, we compared miRNA expression 
profiles of de novo pediatric AML patients that eventually 
relapsed, with those that did not relapse. Subsequently, we 
performed the same comparison, only in the nested subset 
MLL-rearranged AML cases. Of 127 de novo AML cases, 
59/127 (46.5%) relapsed after complete remission (S1 
Table). No statistically significant miRNAs were identified 
when we compared relapsing and non-relapsing cases at 
diagnosis (p=0.643), neither when type II aberrations were 
used as a confounder. Also in the nested cohort of de novo 
pediatric AML MLL-rearranged cases (4 AF6, 7 AF9, 9 
AF10, 1 FNBP1, 1 SEPT6, and 1 NRIP3)(S2 Table), of 
which 14/23 (60.9%) relapsed, no difference in miRNA 
expression profile was found between cases that relapsed 
and cases that recurred (p=0.429).
MiRNAs are differentially expressed in 
initial diagnosis-relapse samples with MLL-
rearrangements
To investigate a potential role for miRNAs in 
clonal evolution towards relapsed disease in pediatric 
MLL-rearranged AML, we conducted miRNA expression 
profiling in a cohort of six paired initial diagnosis-relapse 
samples with various MLL-rearrangements (Table 1). 
A total of 53 significantly (BFDR<0.1) differentially 
expressed miRNAs were identified using the Bayesian 
approach (Figure 1). We observed that all these miRNAs 
were overexpressed (≥2 fold change) in the relapse 
samples compared to the initial diagnosis. None of the 53 
miRNAs, turned out to be significant when were used to 
discriminate the de novo pediatric MLL-rearranged AML 
cases that relapsed from those that did not relapse based 
on miRNA profiles at diagnosis (p= 0.193).
To confirm these findings, we selected 22 miRNAs, 
the top ten most differentially expressed miRNAs 
(Supplementary Figure S1) and 12 potential oncogenic 
miRNAs from literature, out of 53 significant miRNAs 
for validation with stem-loop RT-qPCR. A replication 
set of eight additional initial diagnosis-relapse samples 
with MLL-rearrangements was included in this analysis 
(Table 1). Among these 22 miRNAs, 12 were confirmed 
to be significantly upregulated in the relapse samples 
(Wilcoxon signed rank test; p<0.05), nine failed to pass 
the significance threshold, and one miRNA could not be 
detected in any samples.
The one-sided Wilcoxon signed-rank test was 
used to assess differential expression of the 22 selected 
miRNAs between initial and relapse samples. In 
subsequent analyses, miRNA-532-3p was excluded as 
it was undetectable with RT-qPCR. A significant overall 
difference was found in miRNA expression between the 
initial and relapse (global test p<0,001)(Figure 2 and 
Supplementary Table S3).
MiR-106b-25 cluster is overexpressed in relapsed 
MLL-rearranged AML
Among the 53 identified overexpressed miRNAs, 
miR-106b-5p was ranked as one of the most prominently 
overexpressed miRNAs. MiR-106b clusters together 
with miR-93-5p and miR-25-3p (miR-106b~25 cluster) 
in intron 13 of minichromosome maintenance complex 
component 7 (MCM7) on chromosome 7, which were 
part of the top list differentially expressed miRNAs. This 
cluster is actively co-transcribed as part of the MCM7 
primary RNA transcript [14]. E2F1 transcription factor 1 
(E2F1) acts as an upstream regulator of MCM7 (Figure 
3A). MCM7 mRNA overexpression has previously been 
shown to be associated with poor outcome in solid tumors. 
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Table 1. Characteristics of pediatric MLL-rearranged AML patients included in the paired sample study
ID Array Age (y) Sex WBC  
(x 109/L)
FAB Karyotype sample TP Type 1 
Diagnosis
Type 1 
Relapse
1 MC 1.6 M 16.1 M5
Dx: 46, XY,del(10)(p12), der(11)
(t(10;11)(p12;q2?3)[20]
R: N/A
AF10 NRAS None
2 MC 0.3 F NA NA Dx: UnknownR: Unknown AF9 None None
3 MC 1.2 M 23.0 M7
Dx: 46, XY, t(9;11)(p22;q23)
R: 46, XY [12], 47, XY, t(9;11)
(p22;q23), ?del(18)(q2?1), +19 [1], 
50~53, XY, +6, +6[4], del(9)(q3?3), 
+del(9)(q3?3)[5], t(9;11)(p22;q23), 
-18, ?de;(18)(q2?1), +19, +20, +21, 
+21, +mar1, +mar1 / 46, XY
AF9 None None
4 MC 12.8 M 2.5 M5 Dx: 46, XYR: 46, XY, ?del(11)(p15)[cp5] AF10 None None
5† MC 1.9 M 237.0 M5
Dx: 46, XY, add(11)(q23)
[19]/46,XY[2]
R: 46, XY, add(11)(q23)[24]
AF10 None KRAS
6† MC 7.6 M 129.0 M5
Dx: 46, XY, ?t(3;11)(q26;q12) 
inv(11)(q12q23)]/46, XY[1]
R: 53,XY,?t(3;11)(q26
;q21),+6,+8,+18,+19,+21,+21,+22 
ish t(3;11)(q26;q12)inv(11)
(q12q23) [10]/ 46,XY [6]
AF10 NRAS None
7† V 5.3 M 34.0 M4 or M5
Dx: 46,XY,add(11)(q23),del(12)
(p11p13)[4]/46,XY[22]
R: 46, XY[20]/add(11q23)del(12)
(p12-13)[4]
Unk None None
8 V 1.4 F 3.2 M5
Dx: 46,XX,der(10)ins(10;11)
(p12;q23q13),der(11)?der(11)(p1?)
ins(10;11) [13]/ 46,XX [9]
R: 46,XX,der(10)ins(10;11)
(p12;q23q13),der(11)?der(11)(p1?)
ins(10;11) [13]/ 46,XX [9]
AF10 None None
9 V 10.8 M 67.0 M5
Dx: 46,XY[20]
R: 46,XY[20] ish ins (10;11)
(p;q23q23) (5’ MLL+) [6/10]
AF10 NRAS None
10 V 9.5 F 45.7 M0
Dx: 
51~53,XX,+2,+4,+6,+10,+add(11)
(p?15),+13,-18,+21,+22,inc[cp10]
R: ND
AF10 FLT3-ITD1 None
11 V 14.1 M 42.0 M5
Dx: 46~47,X,der(Y)t(Y,1)
(q12,q12),der(8;12)(q10,q10),+1-
2mar [8]
R: 46~47,X,der(Y)t(Y,1)
(q12,q12),der(8;12)(q10,q10),+1-
2mar [8]
AF10 None None
(Continued )
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ID Array Age (y) Sex WBC  
(x 109/L)
FAB Karyotype sample TP Type 1 
Diagnosis
Type 1 
Relapse
12 V 8.5 M 106.0 M1 Dx: 46,XY,add(11)(q23),incR: 46,XY,add(11)(q23),inc ELL None* WT1
13 V 10.6 F 5.5 M5
Dx: 47, XX, +8, cryptic ins(10;11)
(p1?;q23q23)
R: 45~50, XX, der(1)add(1)(p36)
add(1)(q2?1), der(1)add
AF10 NRAS None
14 V 11.4 M ND M5
Dx: 47,XY,+8,t(11;19)(q23;p13.3)
[9]/46,XY[1]
R: 47,XY,+8,t(11;19)(q23;p13.3)
[6]/46,XY[4]
ENL None None
Abbreviations: WBC indicates white blood cell count; FAB, French American British morphology classification; ND, not 
determined; NA, not available; Dx, diagnosis; R, relapse; Type I mutations screened for NRAS, KRAS, FLT3, PTPN11, 
KIT and WT1. 1) heterozygote; * not screened for WT1; † used for Western blot. MLL translocations were determined 
either with FISH or RT-PCR
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Figure 1: MicroRNA expression in paired initial diagnosis-relapse samples with MLL-rearrangements as determined 
by Taqman Low Density Arrays. Expression of 53 differentially expressed miRNAs as measured by TLDA of 6 paired pediatric AML 
initial-relapse cases with MLL-rearrangements. Expression is significantly higher in relapse samples as compared to initial diagnosis. Data 
are presented as median miRNA changes in relapse (BFDR<0,1).
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Potentially, this may be regulated by overexpression of the 
hosted miRNAs [15, 16].
Therefore, we studied MCM7 and E2F1 mRNA 
(RT-qPCR) expression and could show that they were 
differentially overexpressed in the paired samples with 
MLL-rearrangements at relapse (n=14, p=0.008 and 
p=0.015, respectively)(Figure 3B). Overexpression of 
miR-106b, miR-93 and miR-25 at relapse by miRNA 
profiling, was confirmed by stem loop RT-qPCR in the 
paired patient samples, both in the replication cohort (n=8) 
as in the discovery cohort (n=6) (p<0.05)(Figure 3B).
The expression of the three miRNAs in the 
miR106b~25 cluster were, in general, consistently up- 
or downregulated. Among the 14 cases, four patients 
had one miRNA that showed opposite expression 
compared to the other two miRNAs within the cluster 
(Supplementary Figure S2). It is conceivable, that post-
translational modifications such as alternative splicing of 
the miR-106b~25 transcript may occur, thereby separately 
regulating miR-25 [17], and mutations in the miRNA 
transcript may have induced this difference in expression. 
Therefore, we screened intron 13-14 of MCM7 for 
mutations. We did not identify mutations in intron 13-
14 of MCM7 and observed that the frequency of the 
SNP rs1527423 was similar to that in the normal human 
population (data not shown). All samples (either AF9, 
AF10 or other TPs) showed similar miRNA expression 
(Figure 3B).
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Figure 2: MiRNA expression in paired pediatric AML initial diagnosis-relapse cases with stem-loop RT-qPCR. Median 
miRNA expression levels were determined with single stem loop RT-qPCR per miRNA between initial diagnosis and relapse and are 
significantly different. A large spread is found in miRNA expression levels of validated miRNAs. Data is presented with one-sided P-value.
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Figure 3: Relative expression of E2F1, MCM7, and miR-106b~25 cluster. A. The miR-106b~25 cluster in located intron 13-14 
of MCM7 and cotranscribed together as part of the MCM7 primery RNA transcript. E2F1 regulates MCM7 expression. B. Relative miRNA 
expression of miR-25, miR-93, and miR-106b in 14 paired initial diagnosis-relapse pediatric AML samples with MLL-rearrangements and 
mRNA expression of E2F1 and MCM7. Patients without AF9 or AF10 translocation have comparable miR-106b~25 expression (colored 
lines). Data are presented with one-sided p-values.
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Downstream targets of the miR-106b~25 cluster
Multiple downstream targets for the miR-106b~25 
cluster have been described in different cancer types. 
We selected two predicted targets of the miR-106b~25 
cluster, cyclin-dependent kinase inhibitor 1A (p21WAF1/CIP1) 
and BCL2-like 11 (BIM) [18], based on protein function 
and relevance of these proteins in cancer. In the 14 paired 
samples we did not find differences in p21WAF1/CIP1 (p=0.43) 
or BIM (p=0.36) mRNA expression between initial 
diagnosis and relapse (Figure 4). Of the five paired initial 
diagnosis-relapse samples with MLL-rearrangements gene 
expression profiles (GEP) were available (2 AF9 and 3 
AF10). Although 22 genes were found to be negatively 
correlated with the 53 differentially overexpressed 
miRNAs, p21WAF1/CIP1 and BIM were not negatively 
correlated with GEP (data not shown).
MiRNAs regulate translation of genes through 
translational repression or target mRNA cleavage. Although 
no difference in mRNA expression of p21WAF1/CIP1 and BIM 
could be found, we anticipated that protein level could be 
different. For that reason, we used western blot analysis on 
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Figure 4: Relative expression of p21WAF1/CIP1 and BIM in paired pediatric AML initial diagnosis-relapse cases with 
RT-qPCR (Taqman). Patients used for Western blot have a colored line. Dara are presented with one-sided p-values
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Figure 5: Protein expression anaylis of p21WAF1/CIP1 and BIM with Western blot. Three patients of which protein was 
available were used to validate protein expression of p21WAF1/CIP1 and BIM. Patients 5 and 6 have a MLL-AF10 rearrangement.
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three paired initial diagnosis-relapse samples with MLL-
rearrangements (Table 1). Among two out of three paired 
initial diagnosis-relapse samples, the expression of BIM 
and p21WAF1/CIP1 was downregulated in relapse samples as 
compared to that of initial diagnosis, both in patients with 
a MLL-AF10 translocation. One patient showed a modest 
downregulation of BIM and almost no p21WAF1/CIP1 protein 
expression (Figure 5).
As both p21WAF1/CIP1 and BIM are validated targets in 
prostate cancer and human mammary epithelial cells [18, 
19], we studied p21WAF1/CIP1 and BIM protein expression in 
two MLL-rearranged cell lines, Nomo1 and THP-1, after 
overexpression of the miR-106b~25 cluster. However, we 
found no decreased in BIM protein expression upon forced 
expression of this cluster, while neither MLL-rearranged 
cell line had detectable p21WAF1/CIP1 expression (data not 
shown). Therefore, the identity of these two genes as miR-
106b~25 target remains hypothetical in our study.
DISCUSSION
Over the last years, miRNAs are widely studied 
in the context of cancer development, progression, and 
cancer type classification [20]. Based on miRNA profiling, 
AML samples could be classified according to FAB 
type [21] or cytogenetic information [13]. However, the 
contribution of miRNAs in the process of clonal expansion 
towards relapse in pediatric AML has not been reported 
so far. In this study we aimed to investigate the potential 
role of miRNAs in clonal evolution towards relapse by 
miRNA expression profiling of paired initial diagnosis-
relapse samples with MLL-rearrangements.
In our series of pediatric AML we could not identify 
miRNAs that were predictive for relapse occurrence in 
pediatric AML cases in the diagnostic phase. This may 
have been due to the heterogeneity of selected cases 
(n=127). However, also in a nested more homogeneous 
cohort of MLL-rearranged AML cases, we did not 
identify a miRNA signature that could predict relapse. 
We appreciated the fact that although we studied 23 
cases (of which 9 carried a MLL-AF10 translocation) 
this may, in part, have been due to insufficient power to 
find a specific miRNA signature predictive for relapse 
in poor risk MLL-AML cases. We identified 53 miRNAs 
differentially expressed miRNAs in the development 
towards relapse in MLL-rearranged pediatric AML. These 
differentially expressed miRNAs could however again, not 
predict relapse. Also, this may again underscore the fact 
that clones that are leukemia drivers at relapse, may exist 
only on the subclonal level as has been revealed by NGS 
studies recently [22, 23].
Our results suggest that alternative miRNAs are 
involved in the development of a relapse. This is in 
line with recent findings of Bachas et al. that revealed 
that alternative gene expression profiles and biological 
pathways, are relevant for relapse development, in a 
paired sample analyses of relapsed pediatric AML. 
Approximately, 48% of these paired samples did not 
culminate in the same gene expression cluster. Also, paired 
samples that were in the same cluster had differentially 
expressed genes [24]. This may underscore our findings 
that relapse reflects clonal evolution of small undiscovered 
clones that may be regulated by epigenetic mechanisms, 
rather than by individual genes.
Of the 22 miRNAs that were validated with stem-
loop RT-qPCR, 12 were significantly upregulated, 
including three members of the miR-106b~25 cluster. This 
cluster has also been identified as an oncogenic microRNA 
cluster in other types of cancer, such as gastric, prostate, 
and breast cancer [15, 25, 26]. In total, 19 (out of 22) 
miRNAs that were detectable are more highly expressed 
at relapse compared to initial diagnosis as predicted in 
the discovery cohort. Validation of miRNAs obtained by 
TLDA arrays, especially in small cohorts, is required to 
determine the true significantly different miRNAs.
In four patients, one miRNA within the miR-
106b~25 cluster showed opposite expression. This 
difference could not be explained by the presence of SNP 
rs1527423. No other mutations were found in the miRNA 
gene. Although single miRNAs from this cluster were 
reported in adult AML. Higher miR-25 expression was 
found to be correlated with adverse survival [27], and 
higher miR-93 serum levels were described to be valued 
as potential biomarker for detecting AML in adults [28].
In addition, in the study performed by Emmrich et al 
[13] only miR-106b was significantly higher expressed in 
pediatric AML subtype t(15;17)(q22;q21) (PML/RARA). 
Likewise, only miR-25-5p was significantly lower 
expressed in t(15;17). These findings may underline the 
fact that there is a particular role for this cluster in AML 
leukemogenesis.
We found overexpression of miR-106b~25, E2F1, 
and MCM7 at relapse. The miR-106b~25 cluster, located 
in intron 13 of the MCM7 gene, is actively co-transcribed 
during transcription. It is conceivable that overexpression 
of the miR-106b~25 cluster is regulated by overexpression 
of MCM7. MCM7 is essential for the initiation of 
eukaryotic genome replication and ensuring that the 
whole genome is replicated once per cell cycle [29]. 
Expression of MCM7 is regulated via the activation of the 
transcription factor E2F1 which controls the expression of 
genes encoding various DNA replication proteins and cell 
cycle regulators [30]. Overexpression of E2F1 may lead to 
inappropriate DNA replication and subsequent formation 
of DNA double-stranded breaks result in DNA damage 
[31], thereby resulting in deregulation of hematopoiesis.
Two predicted downstream targets that are targeted 
by the miR-106b~25 cluster were further studied in depth, 
p21WAF1/CIP1 and BIM. We could not show deregulated 
mRNA expression of p21WAF1/CIP1 and BIM at relapse in 
the total group of MLL rearranged patients. However, 
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3 patients (1 AF9, 1 AF10, and 1 ELL) had both lower 
mRNA expression of p21WAF1/CIP1 and BIM at relapse 
and 2 additional patients (2 AF10) had lower p21WAF1/CIP1 
expression at relapse. Difference in protein expression 
could be shown in the three paired initial diagnosis-
relapse samples. Two of the three pairs showed lower 
p21WAF1/CIP1 and BIM protein expression in relapse of 
paired initial diagnosis-relapse samples (AF10). Previous 
studies showed, that, not only miR-106b~25 cluster 
targets p21WAF1/CIP1 and BIM, but also miR-30c and miR-
32 have BIM as validated target [32, 33]. We could show 
that miR-30c and miR-32 were also overexpressed at 
relapse (Supplementary Figure S1). In addition hsa-let-
7a, hsa-let-7e, and miR-301b, predicted by targetscan and 
miRanda to target p21WAF1/CIP1 could also contribute to the 
downregulation of these two targets.
In conclusion, we show that miRNA signatures 
could not predict relapse in a representative cohort 
of pediatric AML, nor in a nested series with MLL-
rearrangements. Based on paired initial diagnosis-relapse 
miRNA analysis we identified 53 miRNAs that may be 
involved in clonal evolution of in the paired samples 
in pediatric MLL-rearranged AML. The miR-106b~25 
cluster may be involved in the development of relapse 
of MLL-rearranged AML which may be caused through 
upregulation of E2F1. Downstream predicted targets of 
this cluster such as p21WAF1/CIP1 and BIM, may be repressed.
MATERIALS AND METHODS
Patient samples
Viably frozen bone marrow or peripheral blood 
samples from 14 paired initial diagnostic and relapsed 
(n=28) pediatric AML cases were provided by the Dutch 
Childhood Oncology Group (DCOG), the AML ‘Berlin–
Frankfurt–Münster’ Study Group (AML-BFM-SG), the 
Czech Pediatric Hematology Group (CPH) and the St. 
Louis Hospital in Paris, France. Informed consent was 
obtained from all patients, after Institutional Review 
Board approval, according to national law and regulations. 
After thawing, samples were enriched to contain at least 
80% leukemic blast cells as previously described [34]. 
Total cellular RNA and genomic DNA were extracted 
using TRIzol reagent (Invitrogen Life Technology, Breda, 
The Netherlands), as previously described [35].
MiRNA and mRNA expression profiling and  
RT-qPCR
MiRNA expression profiling of leukemic cells from 
six paired initial diagnosis-relapse samples AML cases 
were performed. MiRNA expression was measured on 
Taqman Low Density Arrays (TLDA) v2.0 using Taqman 
technology in the 7900 HT Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s instructions.
Differentially expressed miRNAs were validated 
by single stem loop real-time PCR using TaqMan 
MiRNA assay (Applied Biosystem) according to the 
manufacturers’ protocol. The expression levels of miRNA 
target genes (BIM and p21WAF1/CIP) that had been identified 
in other types of cancer, were validated with RT-qPCR 
in 14 paired initial diagnostic-relapse MLL-rearranged 
AML samples, six pairs in the discovery cohort and eight 
additional paired samples with MLL-rearrangements 
(9 AF10, 2 AF9, 1 ELL, 1 ENL, and 1 unknown) in the 
validation cohort. Primers are shown in Supplementary 
Table S4. Messenger-RNA expression was performed 
by RT-qPCR using DyNAmo HS SYBR green (Thermo 
Scientific, Waltham, MA, USA). The average cycle 
threshold (Ct) value was used to calculate miRNA and 
mRNA expression levels relative to the expression level 
of the reference RNU24 or GAPDH, respectively, using 
the comparative Ct method [36].
Western blot
For Western blot, leukemic cells of three paired 
initial diagnosis-relapse samples of patients with MLL-
rearrangements (2 AF10 and 1 unknown) were selected. 
Cells were lysed with Kinase Lysis buffer (KLB) [37], 25 
μg protein per lane was loaded on precast polyacrylamide 
gel (10%, BIO-RAD, Hercules, CA, USA), transferred 
to nitrocellulose membranes using a Trans-Blot Turbo 
Transfer system (BIO-RAD) and probed with α-BIM 
(rabbit mAb (C34C5) and α-p21WAF1/CIP1 (rabbit mAb 
(12D1), (Cell signaling, Danvers, MA, USA). β-actin 
(mouse mAb (ab6276, AC-15), (Abcam, Cambridge, UK) 
was used as loading control. Blots were counterstained 
with IRDye 680/800-labeled secondary antibodies (LI-
COR biosciences, Lincoln, NE, USA).
Statistical analyses
The miRNAs differential expression analysis 
was performed using a Bayesian approach that has 
been implemented in the R-package ShrinkBayes. This 
approach has been known for its robustness in small 
sample series [38]. P-values < 0.05 were considered 
statistically significant for a single test, and Benjamini-
Hochberg corrected false discovery rates (FDR) < 0.1 
were considered statistically significant for multiple tests 
[39]. Statistical analyses were performed using R, version 
3.0. MiRNA profiles were compared using global testing 
with a multinomal regression model [40].
Difference between mRNA and miRNA expression 
levels between paired initial diagnosis-relapse samples, 
as measured by Taqman, were determined using the one-
sided Wilcoxon paired signed rank test.
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